Luke Hoffman, MD, PhD

Luke Hoffman, MD, PhD

Pulmonary and Sleep Medicine, Cystic Fibrosis Research

On staff since September 2004

Academic Title: Associate Professor, Pediatrics

Research Center: Center for Clinical and Translational Research

Lucas R. Hoffman, MD, PhD, is attending physician at Seattle Children's Hospital and associate professor in the Department of Pediatrics at the University of Washington School of Medicine. Hoffman's research focuses on chronic lung infections, particularly in patients with cystic fibrosis (CF). Chronic infections have proven to be particularly difficult to treat with standard antibiotic therapies. For example, the lung infections in children with CF are not improved by antibiotics to the degree we would expect.

Hoffman is working to understand why chronic lung infections are so difficult to treat and how to improve current treatments. Hoffman is also dedicated to the care of patients and to teaching medical students, residents and fellows. His areas of clinical expertise include asthma, CF, bronchopulmonary dysplasia, restrictive lung diseases and the pulmonary complications of neuromuscular disease. He is a member of the American Academy of Pediatrics, the American Thoracic Society, and the American Society for Microbiology.


  • Sarah Ketchikan, AK 11.06.11

    Dr. Hoffman has been a blessing in our lives since the diagnosis of our daughter who has Cysitic Fibrosis. Dr. Hoffman has been our daughter's doctor since 4 months of age. Being from a small isolated community we have traveled countless times to the CF clinic. Dr. Hoffman has been accommodating to us due to difficult travel and has ALWAYS made time to address any questions or concerns big or small. Dr. Hoffman's passion is apparent in the way he interacts with his patients and their families. Dr. Hoffman provides excellent care and considers each step in our daughter's treatment and health maintenance plan carefully. I highly recommend him!

  • Stephanie Lynnwod, WA 03.22.11

    Dr. Hoffman was just a resident when he first cared for our son. Now, as an attending physician, Dr. Hoffman still provides care and consultation for our son, 13 years later. Dr. Hoffman's bedside manner is fantastic. I will always remember him crouching down to speak eye to eye with both patients and parents. His knowledge is extensive and he is always seeking to know more. Finding answers to difficult questions is a strength of Dr. Hoffman's. We highly recommend Dr. Luke Hoffman!


Board Certification(s)

Pediatric Pulmonology

Medical/Professional School

University of California, San Francisco, San Francisco


Pediatrics, University of Washington School of Medicine, Seattle


Pediatric Pulmonology, University of Washington School of Medicine, Seattle

Research Description

We are working to understand why children with chronic lung infections don't improve with antibiotics as predicted based on our knowledge of the microbes involved. As a paradigm for this problem, we focus on the chronic lung infections in people with the genetic disease cystic fibrosis (CF), infections that usually respond incompletely to antibiotics predicted to be effective against the bacteria we know to be present. They exhibit several other characteristics common to many difficult to treat, chronic lung infections, including the following:

1) They frequently include multiple microbial species infecting together, which makes it difficult to know which of these species impact lung disease either by themselves or by interacting with other pathogenic microbes.

2) The chemical and microbial environment in which these infections occur is probably different from that used in laboratory microbial tests, including the availability of nutrients that impact microbial behavior.

Currently, our laboratory studies the behavior of the microbes causing CF and other chronic lung infections in models that attempt to more closely reflect the airway environment, which includes multiple microbial species, antibiotics, and specific nutrients. We hope to identify new and more effective treatments for children with chronic, polymicrobial lung infections, starting with CF.


Research Focus Area

Cystic Fibrosis, Pulmonary

Awards and Honors

Award Name Award Description Awarded By Award Date
Outstanding Teaching Award UW Pediatrics Residency Program 2013
Research feature Discover magazine 2010
Nominee, Seattle Childrens Hospital Family Choice Award Seattle Childrens Hospital 2009
Elected Scholar Institute for Translational Health Sciences 2008
Nominee Seattle Childrens Hospital Family Choice Award 2007
2006 First author of one of 2005s "Top Articles in Infectious Disease" Pediatric News 2006
Leroy Matthews Physician Scientist Award 2004 - 2005
Cystic Fibrosis Foundation Third-year Research Fellowship Training Award Cystic Fibrosis Foundation 2003 - 2004
Cystic Fibrosis Foundation Clinical Fellowship Second-year Training Award Cystic Fibrosis Foundation 2002 - 2003
Cystic Fibrosis Foundation Clinical Fellowship First-year Training Award Cystic Fibrosis Foundation 2001 - 2002
Young Scientist Award Options for the Control of Influenza III, Cairns, Australia 1996
Richard Fineberg Memorial Student Teaching Award UCSF 1994
Invited graduation speaker UC Berkeley 1990
Departmental Citation (valedictorian) College of Chemistry, UC Berkeley 1990
University Citation, (One of top 10 Univ. grads) UC Berkeley 1990
Medical Scientist Training Program Award 1990 - 1998
Thompson Chemistry Scholarship 1988 - 1990
Regents' Scholarship UC Berkeley 1986 - 1990


  • Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, Jacobs MA, Rohmer L, Radey M, Ramsey BW, Brittnacher MJ, Borenstein E, Miller SI
    Escherichia coli Dysbiosis Correlates With Gastrointestinal Dysfunction in Children With Cystic Fibrosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Nov. 20
  • McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM
    Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    Antimicrobial agents and chemotherapy , 2013 Nov. : 57(11)5406-14
  • Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR
    Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Aug. : 57(3)384-91
  • Rogers GB, Hoffman LR, Carroll MP, Bruce KD
    Interpreting infective microbiota: the importance of an ecological perspective.
    Trends in microbiology , 2013 June : 21(6)271-6
  • Hoffman L, Surette M
    What to expect when you're expectorating: cystic fibrosis exacerbations and microbiota.
    Annals of the American Thoracic Society , 2013 June : 10(3)249-50
  • Rogers GB, Cuthbertson L, Hoffman LR, Wing PA, Pope C, Hooftman DA, Lilley AK, Oliver A, Carroll MP, Bruce KD, van der Gast CJ
    Reducing bias in bacterial community analysis of lower respiratory infections.
    The ISME journal , 2013 Apr, : 7(4)697-706
  • Hoffman LR, Ramsey BW
    Cystic fibrosis therapeutics: the road ahead.
    Chest , 2013 Jan. : 143(1)207-13
  • Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B, Bruce KD
    Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience.
    Thorax , 2012 Oct. : 67(10)867-73
  • Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR
    Emerging drugs for bronchiectasis.
    Expert opinion on emerging drugs , 2012 Sept. : 17(3)361-78
  • Rogers GB, Hoffman LR, Döring G
    Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2011 Dec. : 10(6)387-400
  • Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, Hoffman LR, Jones G, Allen CE, Patel N, Forbes B, Tuck A, Bruce KD
    Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2011 Sept. : 10(5)357-65
  • Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD
    Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
    Expert review of molecular diagnostics , 2011 Mar. : 11(2)197-206
  • Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH
    Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
    American journal of respiratory and critical care medicine , 2010 Sept. 1 : 182(5)627-32
  • Rogers GB, Hoffman LR, Whiteley M, Daniels TW, Carroll MP, Bruce KD
    Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.
    Trends in microbiology , 2010 Aug. : 18(8)357-64
  • Elliott D, Burns JL, Hoffman LR
    Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Antimicrobial agents and chemotherapy , 2010 July : 54(7)3024-6
  • Christen M, Kulasekara HD, Christen B, Kulasekara BR, Hoffman LR, Miller SI
    Asymmetrical distribution of the second messenger c-di-GMP upon bacterial cell division.
    Science (New York, N.Y.) , 2010 June 4 : 328(5983)1295-7
  • Carter E, Waldhausen J, Zhang W, Hoffman L, Redding G
    Management of children with empyema: Pleural drainage is not always necessary.
    Pediatric pulmonology , 2010 May : 45(5)475-80
  • Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD
    Comparing the microbiota of the cystic fibrosis lung and human gut.
    Gut microbes , 2010 Mar. : 1(2)85-93
  • Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH
    Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
    Pediatric pulmonology , 2010 Feb. : 45(2)127-34
  • Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, Klausen M, Burns JL, Stahl DA, Hassett DJ, Fang FC, Miller SI
    Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.
    PLoS pathogens , 2010 Jan. 8 : 6(1)e1000712
  • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
    Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan. : 8(1)66-70
  • Luke Hoffman, MD, PhD
    Attachment and Entry of Influenza Virus into Host Cells: Pivotal Roles of the Hemagglutinin
    Structural Biology of Viruses , 1997
  • Luke Hoffman, MD, PhD
    The Low pH-induced Conformational Change in the Influenza Hemagglutinin: Inhibitor Design
    PhD thesis, UCSF , 1996
  • Luke Hoffman, MD, PhD
    Fusion Mechanism of the Influenza Hemagglutinin: Inhibitor Design
    Options for the Control of Influenza III: Proceedings , 1996
  • Luke Hoffman, MD, PhD
    How aspirin works


Presentations Title Event Location Date
What to expect when youre expectorating: An ecological perspective on chronic respiratory infections University of Minnesota Pediatrics Ground Rounds Minneapolis, Minnesota Dec. 11, 2013
CF lung microbiome: What have we learned? The 27th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Salt Lake City, Utah Oct. 24, 2013
Staphylococcus aureus Small-Colony Variants Are Independently Associated With Worse Lung Disease Children With Cystic Fibrosis The 36th European Cystic Fibrosis Conference Lisbon, Portugal June 14, 2013
Pseudomonas aeruginosa adaptation during early CF airway infection and treatment University of Washington Cystic Fibrosis Research Seminar Series Seattle, WA May 9, 2013
Bacterial interspecies interactions during chronic infections: From bedside to bench, and back again Montana State University Departmental Seminar for Microbiology, Immunology, and Infectious Disease (chosen by the graduate students Bozeman, Montana Nov. 2, 2012
Microbial Ecology and Emerging Pathogens. (Workshop Chair and speaker) The 26th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Orlando, FL Oct. 13, 2012
Bacterial interspecies interactions during chronic infections: From the bench to bedside, and back again University of Vermont Center of Biomedical Research Excellence in Immunology and Infectious Diseases Seminar Series University of Vermont, Burlington, VT Sept. 28, 2012
Microbial interspecies interactions during chronic polymicrobial infections University of Washington Department of Microbiology Annual Retreat University of Washington, Seattle, WA Sept. 21, 2012
Chronic lung infections in children: Why dont antibiotics work better? University of Washington Department of Pediatrics Principal Investigator Research Seminar Series University of Washington, Seattle, WA June 18, 2012
The prevalence and clinical significance of Staphylococcus aureus small-colony variants in chronic CF lung infections Queens University Belfast School of Pharmacy Seminar Series Queens University Belfast, Northern Ireland June 5, 2012
Describing the CF Gut Microbiome in Infancy and Early Childhood University of Washington Annual CF Retreat, University of Washington Seattle, WA Aug. 31, 2011
Bacterial adaptation during chronic infections: The role of bacterial interspecies interactions Ross University Research Day (Entitled, "Chronic Infections: A Key Frontier in Infectious Diseases", organized by Lucas Hoffman) Ross University, Dominica Jan. 21, 2011
A research approach to chronic, polymicrobial lung infections Kings College London Molecular Microbiology Research Laboratory Research Seminar Series Kings College London, United Kingdom Nov. 19, 2010
Bacterial adaptive changes during chronic, polymicrobial infections: Lessons from cystic fibrosis University of Washington Microbiology Departmental Seminar, University of Washington Seattle, WA Oct. 5, 2010
Cystic fibrosis exacerbations: A deliberately provocative examination of current antibiotic management Seattle CF Center and Affiliate Centers Annual Clinical Conference, University of Washington Seattle, Washington July 23, 2010
Bacterial adaptive changes during chronic, polymicrobial infections: Lessons from cystic fibrosis Stanford University Department of Pediatrics, Center for Excellence in Pulmonary Biology research seminar Palo Alto, CA Feb. 9, 2010
Bacterial Adaptation During Chronic Infections: Lessons from Cystic Fibrosis University of Montana Division of Biological Sciences Departmental Seminar Missoula, MT Dec. 7, 2009
Evolution and Biofilms The 5th International American Society of Microbiology Conference on Biofilms Cancun, Mexico Nov. 17, 2009
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatment: lasR mutation The 23rd Annual North American CF Conference Minneapolis, MN Oct. 10, 2009
Bacterial Adaptation During Chronic Infections: Lessons from Cystic Fibrosis Vanderbilt University Department of Pediatrics Research Conference Nashville, TN Oct. 5, 2009
The Adaptive Significance of Pseudomonas aeruginosa lasR Mutations in CF : Cystic Fibrosis Research Development Program Annual Retreat, Seattle, WA Aug. 31, 2009
Interspecies Microbial Interactions in CF Airways: Lessons from Pseudomonas and Staphylococcus Cystic Fibrosis Research Development Network Seminar Series Seattle, WA 2009

Research Funding

Grant Title Grantor Amount Award Date
Pseudomonas aeruginosa adaptation During Early Cystic Fibrosis Airway Infection and Treatment Cystic Fibrosis Foundation
Changes in CF Respiratory Microbiota During Treatment With Kalydeco in People with the G551D Mutation NIH
The roles of Staphylococcus aureus and Pseudomonas aeruginosa adapted forms in cystic fibrosis (CF) lung disease Cystic Fibrosis Foundation
Community-level Physiologic Profiling of Whole Cystic Fibrosis Sputum Cystic Fibrosis Foundation
Describing the CF Gut Microbiome in Infancy and Early Childhood NIH
The relationship of fecal microbiomes and nutritional status in CF Cystic Fibrosis Foundation
High-resolution fluorescent microscopic characterization of CF polymicrobial lung infections Cystic Fibrosis Foundation
Staphylococcus aureus small-colony variants: Optimal testing and treatment CCTR
Baby Observational and Nutrition Study Cystic Fibrosis Foundation